Cover Image
Market Research Report

Global Antifungal Drugs Market 2018-2022

Published by TechNavio (Infiniti Research Ltd.) Product code 475046
Published Content info 97 Pages
Delivery time: 1-2 business days
Price
Back to Top
Global Antifungal Drugs Market 2018-2022
Published: December 13, 2018 Content info: 97 Pages
Description

About this market

Use of antifungal infections is expected to drive growth in the market. Research has shown synergism between many antifungals, which has led to an increase in clinicians prescribing combination therapies over monotherapies. Also, availability of antifungals with novel mechanisms of actions has promoted the trend of using combinations. Technavio's analysts have predicted that the antifungal drugs market will register a CAGR of over 3% by 2022.

Market Overview

Increase in antifungal research funding

An increase in funding for antifungal research is another key factor contributing to the growth of the global antifungal drugs market. In many European countries, government funding is also available for research in fungal diseases.

Diagnostic challenges due to non-specific symptoms

Antifungals are often associated with mild adverse effects like itching, redness, abdominal pain, and diarrhea.

For the detailed list of factors that will drive and challenge the growth of the antifungal drugs market during the 2018-2022, view our report.

Competitive Landscape

The market appears to be fragmented and with the presence of several companies including Merck and Pfizer the competitive environment is quite intense. Factors such as the use of antifungal infections and the increase in antifungal research funding, will provide considerable growth opportunities to antifungal drugs manufactures. Astellas Pharma, Basilea Pharmaceutica, Merck, and Pfizer are some of the major companies covered in this report.

Table of Contents
Product Code: IRTNTR23954

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 05: PIPELINE ANALYSIS

  • Fungal infection pipeline

PART 06: MARKET SIZING

  • Market definition
  • Market sizing 2017
  • Market size and forecast 2017-2022

PART 07: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 08: MARKET SEGMENTATION BY ROUTE OF ADMINISTRATION

  • Segmentation by route of administration
  • Comparison by route of administration
  • Topical - Market size and forecast 2017-2022
  • Oral - Market size and forecast 2017-2022
  • Parenteral - Market size and forecast 2017-2022
  • Market opportunity by product

PART 09: CUSTOMER LANDSCAPE

PART 10: REGIONAL LANDSCAPE

  • Geographical segmentation
  • Regional comparison
  • Americas - Market size and forecast 2017-2022
  • EMEA - Market size and forecast 2017-2022
  • APAC - Market size and forecast 2017-2022
  • Market opportunity

PART 11: DECISION FRAMEWORK

PART 12: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 13: MARKET TRENDS

PART 14: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Vendors covered

PART 15: VENDOR ANALYSIS

  • Market positioning of vendors
  • Astellas Pharma
  • Basilea Pharmaceutica
  • Merck
  • Pfizer

PART 16: APPENDIX

  • List of abbreviations

List of Exhibits

  • Exhibit 01: Parent market
  • Exhibit 02: Global antifungals treatment market
  • Exhibit 03: Market characteristics
  • Exhibit 04: Market segments
  • Exhibit 05: Late-stage pipeline drugs against fungal infections
  • Exhibit 06: Market definition - Inclusions and exclusions checklist
  • Exhibit 07: Market size 2017
  • Exhibit 08: Validation techniques employed for market sizing 2017
  • Exhibit 09: Global antifungal drugs market - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 10: Global antifungal drugs market - Year-over-year growth 2018-2022 (%)
  • Exhibit 11: Five forces analysis 2017
  • Exhibit 12: Five forces analysis 2022
  • Exhibit 13: Bargaining power of buyers
  • Exhibit 14: Bargaining power of suppliers
  • Exhibit 15: Threat of new entrants
  • Exhibit 16: Threat of substitutes
  • Exhibit 17: Threat of rivalry
  • Exhibit 18: Market condition - Five forces 2017
  • Exhibit 19: Route of administration - Market share 2017-2022 (%)
  • Exhibit 20: Comparison by route of administration
  • Exhibit 21: Topical - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 22: Topical - Year-over-year growth 2018-2022 (%)
  • Exhibit 23: Oral - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 24: Oral - Year-over-year growth 2018-2022 (%)
  • Exhibit 25: Parenteral - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 26: Parenteral - Year-over-year growth 2018-2022 (%)
  • Exhibit 27: Market opportunity by product
  • Exhibit 28: Customer landscape
  • Exhibit 29: Global antifungal drugs market - Market share by geography 2017-2022 (%)
  • Exhibit 30: Regional comparison
  • Exhibit 31: Americas - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 32: Americas - Year-over-year growth 2018-2022 (%)
  • Exhibit 33: Top 3 countries in Americas
  • Exhibit 34: EMEA - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 35: EMEA - Year-over-year growth 2018-2022 (%)
  • Exhibit 36: Top 3 countries in EMEA
  • Exhibit 37: APAC - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 38: APAC - Year-over-year growth 2018-2022 (%)
  • Exhibit 39: Top 3 countries in APAC
  • Exhibit 40: Market opportunity
  • Exhibit 41: Vendor landscape
  • Exhibit 42: Landscape disruption
  • Exhibit 43: Vendors covered
  • Exhibit 44: Vendor classification
  • Exhibit 45: Market positioning of vendors
  • Exhibit 46: Vendor overview
  • Exhibit 47: Astellas Pharma - Business segments
  • Exhibit 48: Astellas Pharma - Organizational developments
  • Exhibit 49: Astellas Pharma - Geographic focus
  • Exhibit 50: Astellas Pharma - Key offerings
  • Exhibit 51: Vendor overview
  • Exhibit 52: Basilea Pharmaceutica - Business segments
  • Exhibit 53: Basilea Pharmaceutica - Organizational developments
  • Exhibit 54: Basilea Pharmaceutica - Geographic focus
  • Exhibit 55: Basilea Pharmaceutica - Key offerings
  • Exhibit 56: Vendor overview
  • Exhibit 57: Merck - Business segments
  • Exhibit 58: Merck- Organizational developments
  • Exhibit 59: Merck - Geographic focus
  • Exhibit 60: Merck - Segment focus
  • Exhibit 61: Merck - Key offerings
  • Exhibit 62: Vendor overview
  • Exhibit 63: Pfizer - Business segments
  • Exhibit 64: Pfizer - Organizational developments
  • Exhibit 65: Pfizer - Geographic focus
  • Exhibit 66: Pfizer - Segment focus
  • Exhibit 67: Pfizer - Key offerings
Back to Top